BR112023001049A2 - Método para tratamento de doença de enxerto versus hospedeiro causada por transplante de célula-tronco hematopoiética - Google Patents

Método para tratamento de doença de enxerto versus hospedeiro causada por transplante de célula-tronco hematopoiética

Info

Publication number
BR112023001049A2
BR112023001049A2 BR112023001049A BR112023001049A BR112023001049A2 BR 112023001049 A2 BR112023001049 A2 BR 112023001049A2 BR 112023001049 A BR112023001049 A BR 112023001049A BR 112023001049 A BR112023001049 A BR 112023001049A BR 112023001049 A2 BR112023001049 A2 BR 112023001049A2
Authority
BR
Brazil
Prior art keywords
stem cell
hematopoietic stem
host disease
disease caused
cell transplantation
Prior art date
Application number
BR112023001049A
Other languages
English (en)
Portuguese (pt)
Inventor
Cheng Cheungling
Zhao Yanping
Wang Hongjun
Zhong Weiting
Li Jing
Zhao Jing
Liu Weina
Original Assignee
Beijing Tide Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Tide Pharmaceutical Co Ltd filed Critical Beijing Tide Pharmaceutical Co Ltd
Publication of BR112023001049A2 publication Critical patent/BR112023001049A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112023001049A 2020-07-22 2021-07-21 Método para tratamento de doença de enxerto versus hospedeiro causada por transplante de célula-tronco hematopoiética BR112023001049A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010713637 2020-07-22
PCT/CN2021/107575 WO2022017412A1 (zh) 2020-07-22 2021-07-21 治疗造血干细胞移植后的移植物抗宿主病的方法

Publications (1)

Publication Number Publication Date
BR112023001049A2 true BR112023001049A2 (pt) 2023-03-07

Family

ID=79728482

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023001049A BR112023001049A2 (pt) 2020-07-22 2021-07-21 Método para tratamento de doença de enxerto versus hospedeiro causada por transplante de célula-tronco hematopoiética

Country Status (11)

Country Link
US (1) US12702668B2 (cg-RX-API-DMAC7.html)
EP (1) EP4186508A4 (cg-RX-API-DMAC7.html)
JP (1) JP7803924B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230043891A (cg-RX-API-DMAC7.html)
CN (2) CN116322670A (cg-RX-API-DMAC7.html)
AU (1) AU2021313124A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023001049A2 (cg-RX-API-DMAC7.html)
CA (1) CA3186564A1 (cg-RX-API-DMAC7.html)
IL (1) IL299985A (cg-RX-API-DMAC7.html)
TW (2) TW202216691A (cg-RX-API-DMAC7.html)
WO (1) WO2022017412A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3231781A1 (en) * 2021-09-18 2023-03-23 Beijing Tide Pharmaceutical Co., Ltd. Solid form of rho-associated protein kinase inhibitor or solvate thereof, preparation method and use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011009568A (es) * 2009-03-09 2011-12-06 Surface Logix Inc Inhibidores de la rho cinasa.
RS63503B1 (sr) * 2012-10-05 2022-09-30 Kadmon Corporation Llc Inhibitori rho kinaze
EP3504204A4 (en) 2016-08-26 2020-05-27 Lycera Corporation INDAZOLYL-L, 2,4-THIADIAZOLAMINE AND RELATED COMPOUNDS FOR INHIBITING RHO-ASSOCIATED PROTEIN KINASES AND FOR TREATING DISEASES
WO2019000683A1 (zh) 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
JP7311228B2 (ja) * 2017-06-30 2023-07-19 ベイジン タイド ファーマシューティカル カンパニー リミテッド Rho-関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用
US10329282B2 (en) * 2017-06-30 2019-06-25 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof
TWI818919B (zh) 2017-08-15 2023-10-21 美商歐米諾斯公司 用於治療和/ 或預防與造血幹細胞移植有關的移植物抗宿主病和/ 或瀰漫性肺泡出血和/ 或靜脈閉塞性病的方法

Also Published As

Publication number Publication date
CA3186564A1 (en) 2022-01-27
JP2023535035A (ja) 2023-08-15
TWI868660B (zh) 2025-01-01
CN121846099A (zh) 2026-04-14
EP4186508A4 (en) 2024-10-16
WO2022017412A1 (zh) 2022-01-27
AU2021313124A1 (en) 2023-03-09
CN116322670A (zh) 2023-06-23
EP4186508A1 (en) 2023-05-31
JP7803924B2 (ja) 2026-01-21
US12702668B2 (en) 2026-08-11
US20230285393A1 (en) 2023-09-14
IL299985A (en) 2023-03-01
TW202327609A (zh) 2023-07-16
KR20230043891A (ko) 2023-03-31
TW202216691A (zh) 2022-05-01

Similar Documents

Publication Publication Date Title
BR112023001195A2 (pt) Composto ou racemato, estereoisômero, tautômero, composto isotopicamente rotulado, solvato, polimorfo, sal farmaceuticamente aceitável ou composto pró-fármaco do mesmo, composto, método de preparação para composto ou racemato, estereoisômero, tautômero, composto isotopicamente rotulado, solvato, polimorfo, sal farmaceuticamente aceitável ou composto de pró-fármaco, composição farmacêutica, método para tratar uma doença associada com a ativação do caminho alternativo de complemento, e, uso do composto
CO2023001407A2 (es) Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y métodos de uso de los mismos
BR112021026214A2 (pt) Método para tratamento de fibrose pulmonar idiopática
BR112022008020A2 (pt) Métodos de tratamento de doenças e distúrbios relacionados a lsd1 com inibidores de lsd1
ECSP22019360A (es) Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos
BR112021014525A8 (pt) Inibidor de jak e método de preparação do mesmo
CR20210477A (es) Compuestos de aza-benzotiofeno y aza-benzofurano como antihelmínticos
BR112015020600A2 (pt) composição farmacêutica, método para o tratamento de e/ou melhorar doenças de gordura no fígado de origem não alcoólica e uso da composição
MX2025007797A (es) Derivado de tetrahidrotiofeno y uso de este en medicina
ZA202400988B (en) Aak1 inhibitor and use thereof
BR112022016448A2 (pt) Método para tratamento de doença do enxerto contra hospedeiro crônica
MX2024010099A (es) Derivado de pirazolopiridina y aplicacion del mismo en medicina.
DOP2023000060A (es) Inhibidores de la línea-1 para tratar enfermedades antecedentes de la invención
MX2021008010A (es) Composiciones y métodos para tratar las enfermedades del hígado graso no alcohólico (nafld).
BR112022002107A2 (pt) Inibidor de vmat2 e método de preparação para o mesmo e aplicação do mesmo
CL2020003143A1 (es) Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitario para el tratamiento de una enfermedad parasitaria
WO2021207682A3 (en) Pi3 kinase inhibitors and uses thereof
MX2020004667A (es) Compuestos, composiciones y metodos para el tratamiento de trastornos oculares y enfermedades cutaneas.
MX2022011242A (es) Inmunomodulación de o-het/aril azálidos.
BR112023025251A2 (pt) Composto ou sal, éster, solvato, pró-fármaco, derivado marcado com isótopo ou isômero farmaceuticamente aceitável deste, composição, composição farmacêutica e método para tratamento de uma doença ou distúrbio inibindo a transdução de sinal mediada por tyk2
EP2150550A4 (en) NEW CARBAMOYLOXY-ARYL-ALKAN-ARYLPIPERAZIN COMPOUND, PHARMACEUTICAL COMPOSITIONS WITH THE COMPOUND AND METHOD FOR THE TREATMENT OF PAIN, FEAR STATES AND DEPRESSION BY MEANS OF ADMINISTRATION OF THE COMPOUND
AR129959A1 (es) Método para tratar enfermedades o trastornos orgánicos con inhibidores de ask1
MX2025012154A (es) Compuestos de pirimidina disustituidos para la inhibición de cetohexocinasa
MX2024002892A (es) Azalidos inmunomoduladores.
MX2025011536A (es) Forma polimorfica del clorhidrato de pitolisant